Vyvanse - (20, 30, 40, 50, 60, 70 mg capsules)

Generic Name	Lisdexamfetamine Dimesylate	**Innovator**	Shire
Dosage	20, 30, 40, 50, 60, 70 mg capsules	**Branded US Sales**	More Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) Moderate to Severe Binge Eating Disorder (BED) in adults		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Vyvanse - (10 mg; Capsule)

Generic Name	Lisdexamfetamine Dimesylate	**Innovator**	Takeda
Dosage	10 mg; Capsule	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Vyvanse is indicated for the treatment of: Moderate to Severe Binge Eating Disorder (BED) in adults		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.